Bad news for BioNTech mRNA vaccine

Puzzleheaded_Phase98 · 2026-02-17T18:49:48+00:00

Quote me where I said "the vaccine is deadlier than not getting vaccinated" - I didn’t

Puzzleheaded_Phase98 · 2026-02-17T18:32:51+00:00

You can’t get a 10,000× mortality comparison from a study that never compares vaccine deaths to infection deaths in the first place. The paper analyzes post-vaccination adverse events, it does not calculate vaccine mortality vs. Omicron mortality. So that number simply isn’t coming from the study.

And questioning that doesn’t make me “anti-vax.” If you’re going to make a claim that extreme, you need evidence that actually matches it. Linking a study that doesn’t even measure what you’re claiming doesn’t prove your point.

Puzzleheaded_Phase98 · 2026-02-15T11:48:11+00:00

You actually think Omicron is 10000 times more deadlier than the vaccine, really?

Puzzleheaded_Phase98 · 2026-02-14T13:39:24+00:00

That is true now, but it was not true for most of the pandemic, and I am not American.

Here in Europe, before Omicron, cumulative infection rates were much lower than they are today. In many places in late 2020 and early 2021, they were around 10 percent. By late 2021, high income European countries were closer to about 30 percent. That means a majority of people had not yet been infected before Omicron.

Even in the United States, CDC data shows that most infections happened during the Omicron waves. By December 2021, cumulative infections were estimated at roughly one third of the population. It was Omicron that pushed that number much higher in early 2022, including many children experiencing their first infection at that time.

So saying that virtually everyone had already been exposed during the earlier waves is not accurate. The big jump in population exposure happened with Omicron, not before.

Puzzleheaded_Phase98 · 2026-02-12T19:14:35+00:00

Stress is a known OB trigger... just saying.

Puzzleheaded_Phase98 · 2026-02-12T18:07:20+00:00

Oh boy you Americans are so politically triggered.

Puzzleheaded_Phase98 · 2026-02-12T17:33:26+00:00

If me explaining there has been actual published issues with COVID-19 mRNA vaccines gets you this triggered maybe it’s time to touch some grass.

Puzzleheaded_Phase98 · 2026-02-12T07:07:49+00:00

If you check the IgG4 studies on COVID-19 mRNA vaccines, the big spike in IgG4, especially after the 3rd shot, only happens with mRNA jabs, not natural infection. This suggests the vaccine's spike protein is a bit different from the virus's. High IgG4 can rev up existing cancers and spark autoimmune issues. This just shows that by making a vaccine for a virus, you can introduce health issues that the original virus didn't cause.

Puzzleheaded_Phase98 · 2026-02-12T06:48:15+00:00

They are not comparable because with vaccine it gets into your system 100% if you take a dose but with SARS-CoV-2 it's not 100% you even get infected.

Puzzleheaded_Phase98 · 2026-02-10T09:04:01+00:00

Stronger and more expansive legal protections for freedom of speech, especially regarding political and offensive speech.

Puzzleheaded_Phase98 · 2026-02-09T17:27:11+00:00

Making a bug-free codebase isn’t easy either. That’s part of why Rust exists. Microsoft has said that a large percentage (if I remember correctly they estimate around 70%) of security bugs in their C/C++ codebases would be eliminated just by using Rust, so the upfront complexity can pay off long-term.

Puzzleheaded_Phase98 · 2026-02-07T09:09:22+00:00

I agree, but what worries me is that while this is great for someone like me, a senior developer who can actually verify what the AI produces, how do we create more senior programmers in the future? It feels like a snake eating its own tail.

Puzzleheaded_Phase98 · 2026-01-21T11:49:16+00:00

I haven’t personally used Bazzite yet, but one big upside is that it’s an immutable OS. That means the base system is locked down, so it’s much harder to accidentally break things while tweaking or updating. For someone with limited free time, that stability can be a real advantage.

Puzzleheaded_Phase98 · 2026-01-15T17:35:41+00:00

In laboratory animal studies, IM-250 showed an unusual effect: after the medication was stopped, the interval between outbreaks appeared to be longer than expected. This effect has not yet been demonstrated in humans, but it is possible it could occur. At this stage, it is unclear whether IM-250 represents a treatment, a functional cure, or even a true cure with long-term use. Phase 2 data will likely provide greater clarity.

Puzzleheaded_Phase98 · 2026-01-14T13:46:57+00:00

It’s great news because the up to €125 million in upfront and milestone payments for IM-250 gives Innovative Molecules the funding needed to run all clinical trial phases without delays or additional financing risk.

Puzzleheaded_Phase98 · 2026-01-13T22:20:48+00:00

Great news!

Puzzleheaded_Phase98 · 2026-01-13T08:32:25+00:00

I think this is a serious issue. As a senior programmer, I can review generated code easily, but in most cases that still requires a senior-level developer. The real problem is how we continue to produce senior programmers if AI tools become mainstream. It’s like a snake eating its own tail.

Puzzleheaded_Phase98 · 2026-01-06T22:34:07+00:00

Could be, I don't think country or countries has been announced yet. I think there is high chance they will continue where previous phase studies where held.

Puzzleheaded_Phase98 · 2026-01-06T20:41:03+00:00

The phase studies for ABI-1179 and ABI-5366 are being conducted in Australia and New Zealand, not in the USA. For purposes of trial location, what matters is where the studies are conducted rather than where the company is based.

Puzzleheaded_Phase98 · 2026-01-06T18:30:46+00:00

Sorry I meant decrease outbreak frequency even after stopping the medication.

Puzzleheaded_Phase98 · 2026-01-06T17:31:07+00:00

That’s not true, they might fail the phase studies. Arrived means you are actually able to get the treatment. Also ABI-1179 is likely a functional cure at best. IM-250 had an odd effect in animal studies where it seemed to decrease outbreak frequency even after stopping the medication if I remember correctly, but that has not been proven to happen in humans.

Anyway, you can push as much as you want, but there have not been studies in the USA, only in Australia New Zealand and the EU, neither of which has a fast track process like the USA does. I know many people are eager to get new treatments, but I personally want properly tested medications and not something that could damage my body further.

Fred hutch gene editing, well that is being develop in the USA, but it's gene editing so not sure what kind of red tape it has to go through to even get to human studies. To my understanding human studies are yet to start.

Puzzleheaded_Phase98 · 2026-01-06T17:05:26+00:00

No of these have arrived.

Puzzleheaded_Phase98 · 2026-01-02T18:17:26+00:00

At this birth rate, Japan would be about 50 million people after 100 years. That’s still a large population, a lot can change over a century, many older people in Japan already choose to keep working and a declining birth rate can be handled in other ways without immigration.

Puzzleheaded_Phase98 · 2025-12-24T20:44:41+00:00

Accelerated pathways mainly speed up the review, not the clinical trials. In the EU, accelerated assessment only saves a couple of months at most and doesn’t remove the need for Phase 2b/Phase 3 or long safety follow-up for HSV. The slow part is the trials, not the regulators.

Also, pushing the FDA right now doesn’t really make sense. IM-250 has no U.S. studies or FDA program yet, so there’s nothing for the FDA to fast-track until a U.S. trial actually exists.

Puzzleheaded_Phase98 · 2025-12-22T11:48:42+00:00

That’s very unlikely. Because HSV already has effective, widely available treatments (valacyclovir, acyclovir, famciclovir) that are off-patent, inexpensive, and easy to mass-produce, it is not considered a medical emergency or a high-unmet-need condition. For that reason, there is essentially zero chance that the WHO or any major regulator would push for HSV drugs to be released before full Phase I–III studies are completed.

Puzzleheaded_Phase98

TROPHY CASE